Referências

1. http://www2.inca.gov.br/wps/wcm/connect/inca/portal/home
2. http://www.fosp.saude.sp.gov.br/publicacoes/registrohospitalardecancer
3. Início - DATASUS, , http://datasus.saude.gov.br/
4. Saslow, D., Solomon, D., Lawson, H.W., Killackey, M., Kulasingam, S.L., Cain, J., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer (2012) Am J Clin Pathol, 137 (4), pp. 516-542
5. Guidelines & Resources, , http://www.chestnet.org/Guidelines-and-Resources, American College of Chest Physicians
6. Dalton, S.O., Steding-Jessen, M., Jakobsen, E., Mellemgaard, A., Østerlind, K., Schüz, J., Socioeconomic position and survival after lung cancer: Influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004-2010 (2015) Acta Oncol, 54 (5), pp. 797-804
7. Forrest, L.F., Adams, J., Wareham, H., Rubin, G., White, M., Socioeconomic inequalities in lung cancer treatment: Systematic review and meta-analysis (2013) Plos Med, 10 (2)
8. Listagem De Pps, , https://www.cremesp.org.br/pdfs/
9. Tedde, M.L., Petrere, O., Pinto Filho, D.R., Pereira, S., Monteiro, R., Sassaki, A.M., General thoracic surgery workforce: training, migration and practice profile in Brazil (2015) Eur J Cardiothorac Surg, 47 (1), pp. e19-e24
10. Terra, R.M., Kazantzis, T., Pinto-Filho, D.R., Camargo, S.M., Martins-Neto, F., Guimarães, A.N., Anatomic pulmonary resection by video-assisted thoracoscopy: The Brazilian experience (VATS Brazil study) (2016) J Bras Pneumol, 42 (3), pp. 215-221
11. Sociedade Brasileira De Radioterapia, , http://sbradioterapia.com.br/
12. Slotman, B.J., Cottier, B., Bentzen, S.M., Heeren, G., Lievens, Y., Van Den Bogaert, W., Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: Work package 1 (2005) Radiother Oncol, 75 (3), pp. 349-354
13. Chang, J.Y., Kestin, L.L., Barriger, R.B., Chetty, I.J., Ginsburg, M.E., Kumar, S., ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: Good performance status/definitive intent (2014) Oncology (Williston Park), 28 (8), pp. 706-714
14. Jones, A.P., Haynes, R., Sauerzapf, V., Crawford, S.M., Zhao, H., Forman, D., Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer (2008) Eur J Cancer, 44 (7), pp. 992-999
15. Wu, J., Kerba, M., Wong, R., McKimmon, E., Eigl, B., Hagen, N.A., Patterns of practice in palliative radiotherapy for painful bone metastases: Impact of a regional rapid access clinic on access to care (2010) Int J Radiat Oncol Biol Phys, 78 (2), pp. 533-538
16. Tiwana, M.S., Barnes, M., Kiraly, A., Olson, R.A., Utilization of palliative radiotherapy for bone metastases near end of life in a population-based cohort (2016) BMC Palliat Care, 15 (1), pp. 1-5
17. Página Inicial — Governo Do Brasil, , http://www.brasil.gov.br/, Accessed 2018 Oct 3
18. Howington, J.A., Blum, M.G., Chang, A.C., Balekian, A.A., Murthy, S.C., Treatment of stage I and II nonsmall cell lung cancer: Diagnosis and management of lung cancer (2013) Chest, 143 (5), pp. e278S-e313S. , 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
19. Bradley, J., Graham, M.V., Winter, K., Purdy, J.A., Komaki, R., Roa, W.H., Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma (2005) Int J Radiat Oncol Biol Phys, 61 (2), pp. 318-328
20. (2011) NCI Dictionary of Cancer Terms, , https://www.cancer.gov/publications/dictionaries/cancer-terms, National Cancer Institute
21. Groome, P.A., Bolejack, V., Crowley, J.J., Kennedy, C., Krasnik, M., Sobin, L.H., The IASLC Lung Cancer Staging Project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours (2007) J Thorac Oncol, 2 (8), pp. 694-705
22. Postmus, P.E., Kerr, K.M., Oudkerk, M., Senan, S., Waller, D.A., Vansteenkiste, J., Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017) Ann Oncol, 28, pp. iv1-iv21. , 1
23. Artal Cortés, Á., Calera Urquizu, L., Hernando Cubero, J., Adjuvant chemotherapy in non-small cell lung cancer: State-of-the-art (2015) Transl Lung Cancer Res, 4 (2), pp. 191-197
24. Pignon, J.-P., Tribodet, H., Scagliotti, G.V., Douillard, J.-Y., Shepherd, F.A., Stephens, R.J., Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group (2008) Am J Clin Oncol, 26 (21), pp. 3552-3559
25. Simon, G.R., Manegold, C., Barker, S.S., Treat, J.A., Visseren-Grul, C., Obasaju, C., Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer (2013) Clin Lung Cancer, 14 (6), pp. 601-608
26. Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data (2014) The Lancet, 383 (9928), pp. 1561-1571
27. Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta- Analysis of Individual Patient Data From 16 Randomized Controlled Trials (2008) J Clin Oncol, 26 (28), pp. 4617-4625
28. Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982) Am J Clin Oncol, 5 (6), pp. 649-655
29. Langer, C.J., The “lazarus response” in treatment-naive, poor performance status patients with nonsmall- cell lung cancer and epidermal growth factor receptor mutation (2009) Am J Clin Oncol, 27 (9), pp. 1350-1354
30. Travis, W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J., Beasley, M.B., The 2015 World Health Organization classification of lung tumors (2015) J Thorac Oncol, 10 (9), pp. 1243-1260
31. Lima, E.A., Sales, P.G., Vilaça, I., Perillo, F., Almeida, F., Martins, G., P3.07-021 Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (2017) J Thorac Oncol, 12 (1), pp. S1443-S1444
32. Midha, A., Dearden, S., McCormack, R., EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII) (2015) Am J Cancer Res, 5 (9), pp. 2892-2911
33. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer (2016) N Engl J Med, 375 (19), pp. 1823-1833
34. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer (2002) N Engl J Med, 346 (2), pp. 92-98
35. Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F.V., Schiller, J.H., Paesmans, M., Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis (2007) J Natl Cancer Inst, 99 (11), pp. 847-857
36. Pérez-Moreno, M.A., Galván-Banqueri, M., Flores-Moreno, S., Villalba-Moreno, A., Cotrina-Luque, J., Bautista-Paloma, F.J., Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer (2014) Int J Clin Pharm, 36 (3), pp. 476-487
37. Scagliotti, G.V., Parikh, P., Von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer (2008) J Clin Oncol, 26 (21), pp. 3543-3551
38. Rossi, A., Chiodini, P., Sun, J.-M., O’Brien, M., Von Plessen, C., Barata, F., Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data (2014) Lancet Oncol, 15 (11), pp. 1254-1262
39. Paz-Ares, L.G., De Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (2013) J Clin Oncol, 31 (23), pp. 2895-2902
40. Keating, G.M., Bevacizumab: A review of its use in advanced cancer (2014) Drugs, 74 (16), pp. 1891-1925
41. Carmeliet, P., VEGF as a key mediator of angiogenesis in cancer (2005) Oncology, 69, pp. 4-10
42. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Paclitaxel-Carboplatin alone or with bevacizumab for non-small-cell lung cancer (2006) N Engl J Med, 355 (24), pp. 2542-2550
43. Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer (2004) J Clin Oncol, 22 (11), pp. 2184-2191
44. Collisson, E.A., Campbell, J.D., Brooks, A.N., Berger, A.H., Lee, W., Comprehensive molecular profiling of lung adenocarcinoma (2014) Nature, 514 (7521), p. 262
45. Mayekar, M.K., Bivona, T.G., Current landscape of targeted therapy in lung cancer (2017) Clin Pharmacol Ther, 102 (5), pp. 757-764
46. Lindeman, N.I., Cagle, P.T., Beasley, M.B., Chitale, D.A., Dacic, S., Giaccone, G., Molecular testing guideline for selection of lung cancer patients for egfr and alk tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (2013) J Thorac Oncol, 8 (7), pp. 823-859
47. Rolfo, C., Mack, P.C., Scagliotti, G.V., Baas, P., Barlesi, F., Bivona, T.G., Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC (2018) J Thorac Oncol, 13 (9), pp. 1248-1268
48. Yewale, C., Baradia, D., Vhora, I., Patil, S., Misra, A., Epidermal growth factor receptor targeting in cancer: A review of trends and strategies (2013) Biomaterials, 34 (34), pp. 8690-8707
49. Poster sessions (2015) J Thorac Oncol, 10 (9), pp. S407-S760
50. Graham, R.P., Treece, A.L., Lindeman, N.I., Vasalos, P., Shan, M., Jennings, L.J., Worldwide frequency of commonly detected EGFR mutations (2018) Arch Pathol Lab Med, 142 (2), pp. 163-167
51. Normando, S., Cruz, F.M., Del Giglio, A., Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer (2015) Anticancer Drugs, 26 (9), pp. 995-1003
52. Xu, H., Minchella, K., Zhou, D., Al-Huniti, N., A meta-analysis of the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients (2016) J Clin Oncol, 34, p. e20604
53. Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebocontrolled phase 3 study (2010) Lancet Oncol, 11 (6), pp. 521-529
54. Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M.G., Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) Ann Oncol, 27, pp. v1-27
55. Bilsland, J.G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K.A., Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications (2008) Neuropsycho-Pharmacology, 33 (3), pp. 685-700
56. Li, Y., Milner, P., Chauhan, A., Watson, M., Hoffman, R., Kodner, C., Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity (1990) Science, 250 (4988), pp. 1690-1694
57. Chen, Y., Takita, J., Choi, Y.L., Kato, M., Ohira, M., Sanada, M., Oncogenic mutations of ALK kinase in neuroblastoma (2008) Nature, 455 (7215), pp. 971-974
58. Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system (1997) Oncogene, 14 (4), pp. 439-449
59. Solomon, B.J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., First-line crizotinib versus chemotherapy in ALK-positive lung cancer (2014) N Engl J Med, 371 (23), pp. 2167-2177
60. Peters, S., Camidge, D.R., Shaw, A.T., Gadgeel, S., Ahn, J.S., Kim, D.-W., Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (2017) N Engl J Med, 377 (9), pp. 829-838
61. Kim, D.-W., Tiseo, M., Ahn, M.-J., Reckamp, K.L., Hansen, K.H., Kim, S.-W., Brigatinib in Patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase II trial (2017) J Clin Oncol, 35 (22), pp. 2490-2498
62. Soria, J.-C., Tan, D., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND- 4): A randomised, open-label, phase 3 study (2017) Lancet, 389 (10072), pp. 917-929
63. Chan, B.A., Hughes, B.G.M., Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future (2015) Transl Lung Cancer Res, 4 (1), pp. 36-54
64. Weiden, J., Tel, J., Figdor, C.G., Synthetic immune niches for cancer immunotherapy (2017) Nat Rev Immunol, 18, pp. 212-219
65. Sharpe, A.H., Pauken, K.E., The diverse functions of the PD1 inhibitory pathway (2017) Nat Rev Immunol, 18, pp. 153-167
66. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W., Poddubskaya, E., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer (2015) N Engl J Med, 373 (2), pp. 123-135
67. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer (2015) N Engl J Med, 373 (17), pp. 1627-1639
68. Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): A randomised controlled trial (2016) Lancet, 387 (10027), pp. 1540-1550
69. Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study (2018) J Clin Oncol, 36 (17), pp. 1675-1684
70. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., Von Pawel, J., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy (2004) J Clin Oncol, 22 (9), pp. 1589-1597
71. Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (2000) J Clin Oncol, 18 (10), pp. 2095-2103
72. Garassino, M.C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial (2013) Lancet Oncol, 14 (10), pp. 981-988
73. Kawaguchi, T., Ando, M., Asami, K., Okano, Y., Fukuda, M., Nakagawa, H., Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-smallcell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA) (2014) J Clin Oncol, 32 (18), pp. 1902-1908
74. Crinò, L., Cappuzzo, F., Gemcitabine in non-small cell lung cancer (2002) Expert Opin Pharmacother, 3 (6), pp. 745-753
75. Julien, S., Jacoulet, P., Dubiez, A., Westeel, V., Depierre, A., Non-small cell lung cancer: A study of longterm survival after vinorelbine monotherapy (2000) Oncologist, 5 (2), pp. 115-119